Mymetics Corp (MYMX)

[Work Harder]

MYMX Holding PATENTS on VIROSOMES, manufacturing, & antigens~!!!!!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135234129

METHODS FOR PROVIDING ADJUVANTED VIROSOMES AND ADJUVANTED VIROSOMES OBTAINABLE THEREBY

Applicants

BESTEWIL HOLDING B.V. [NL]/[NL]

Agents

JANSEN, C.M.

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016039619&tab=SEARCHREPORT

6. Method according to any one of the preceding claims, wherein the membrane fusion protein is a viral fusion protein, preferably selected from the group consisting of the HIV gp l20/gp41 proteins, the paramyxovirus F proteins and the influenza virus hemagglutinin (HA) protein, the gp64 protein of baculo virus, the E proteins of Semliki Forest virus, and fusion active variants thereof.

21. Method according to claim 19, wherein the membrane anchoring moiety is a lipid moiety, preferably a phospholipid or acyl chain.

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016039619&tab=PCTCLAIMS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

(4)A BUNGENER LAURA ET AL, "A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease", ANTIVIRAL THERAPY- AN OFFICIAL PUBLICATION OF THE INTERNATIONAL SOCIETY FOR ANTIVIRAL RESEARCH, MTM PUBLICATIONS, LONDON, GB,Vol. 11, No. 6, 01 January 2006 (2006-01-01), page 717-727,
XP009184211
ISSN:1359-6535
1-35
cited in the application

(5) A SCHWANINGER R ET AL, "Virosomes as new carrier system for cancer vaccines", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE,Vol. 53, No. 11, 01 November 2004 (2004-11-01), page 1005-1017,
XP002316694
DOI: 10.1007/S00262-004-0545-5 external link
ISSN:0340-7004
1-35
the whole document

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016039619&tab=SEARCHREPORT

Ok, so who is the oncology partner in the Netherlands

Jansen ?

Mymx has something w/ IO Biotech that isn't exactly in the Netherlands

As does Merck

The RSV patent is listed as a caner antigen

Collaboration possible in cancer immunotherapy either in combination with check point blockade or enhancing the response rates of existing cancer antigens by using our safe, proven, GMP ready proprietary virosome based vaccine platform (known for specific CD8+ and CD4+ Tcell increase)

https://www.swissbiotech.org/listing/mymetics-sa/

Show us the money Dr Kempers